Katherine Stueland Sells 51,420 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 51,420 shares of GeneDx stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60. Following the transaction, the chief executive officer now owns 1,720 shares of the company’s stock, valued at $162,505.60. The trade was a 96.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total transaction of $1,407,709.08.
• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total value of $805,951.75.
• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The shares were sold at an average price of $76.37, for a total value of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The shares were sold at an average price of $70.34, for a total transaction of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total transaction of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total value of $143,456.40.

GeneDx Trading Down 7.4 %

Shares of WGS stock opened at $89.38 on Friday. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a twelve month low of $2.85 and a twelve month high of $98.87. The company’s 50-day moving average price is $78.01 and its 200-day moving average price is $53.38. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of -28.74 and a beta of 2.02.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.25. The company had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. GeneDx’s revenue was up 44.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.82) EPS. As a group, equities analysts predict that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Institutional Investors Weigh In On GeneDx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp purchased a new position in shares of GeneDx during the 2nd quarter worth approximately $991,000. Rhumbline Advisers lifted its stake in GeneDx by 8,096.4% during the second quarter. Rhumbline Advisers now owns 18,360 shares of the company’s stock worth $480,000 after purchasing an additional 18,136 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of GeneDx during the second quarter worth $34,000. American Century Companies Inc. grew its stake in shares of GeneDx by 36.1% in the second quarter. American Century Companies Inc. now owns 17,258 shares of the company’s stock valued at $451,000 after buying an additional 4,573 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of GeneDx in the 2nd quarter valued at $2,362,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Craig Hallum lifted their price target on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Wells Fargo & Company upped their target price on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. The Goldman Sachs Group raised their price target on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Finally, TD Cowen upped their price objective on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $70.67.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.